Bontoux Christophe, Benzaquen Jonathan, Hofman Véronique, Heeke Simon, Hannetel Paul, Capela-Brosseau-Laborde Pierre, Marquette Charles-Hugo, Ilié Marius, Hofman Paul
Laboratory of Clinical and Experimental Pathology, Université Côte d'Azur, Pasteur Hospital, Centre Hospitalier Universitaire de Nice, Biobank BB-0033-00025, 06000 Nice, France.
IRCAN Team 4, Inserm U1081/CNRS 7284, Centre de Lutte Contre le Cancer Antoine Lacassagne, 06000 Nice, France.
J Pers Med. 2022 Oct 4;12(10):1651. doi: 10.3390/jpm12101651.
Despite the recent increase in the number of types of treatments, non-small-cell lung cancer (NSCLC) remains the major cause of death from cancer worldwide. So, there is an urgent need to develop new therapeutic strategies. The gene codes for tyrosine kinase receptor whose alterations are known to drive carcinogenesis. alterations, including amplification, mutations, and overexpression, have been mainly described in breast and gastric cancers, but up to 4% of NSCLC harbor actionable mutations. HER2-targeted therapy for NSCLC with trastuzumab, pertuzumab, and trastuzumab emtansine has failed to demonstrate an improvement in survival. Nevertheless, recent data from phase II trials have shed light on promising specific therapies for -mutant NSCLC such as trastuzumab deruxtecan. Herein, we aimed to provide an updated review on the biology, epidemiology, molecular testing, and therapeutic strategies for NSCLC with molecular alterations.
尽管最近治疗类型有所增加，但非小细胞肺癌（NSCLC）仍然是全球癌症死亡的主要原因。因此，迫切需要开发新的治疗策略。该基因编码酪氨酸激酶受体，已知其改变会驱动致癌作用。这些改变，包括扩增、突变和过表达，主要在乳腺癌和胃癌中被描述，但高达4%的NSCLC存在可靶向治疗的突变。使用曲妥珠单抗、帕妥珠单抗和曲妥珠单抗 emtansine对NSCLC进行HER2靶向治疗未能证明生存期有所改善。然而，II期试验的最新数据为针对突变型NSCLC的有前景的特异性疗法提供了线索，如曲妥珠单抗 deruxtecan。在此，我们旨在提供关于具有分子改变的NSCLC的生物学、流行病学、分子检测和治疗策略的最新综述。
